605. Clinical Characteristics and Outcomes Among Travelers With Severe Dengue : A GeoSentinel Analysis.
作者: Ralph Huits.;Kristina M Angelo.;Bhawana Amatya.;Sapha Barkati.;Elizabeth D Barnett.;Emmanuel Bottieau.;Hannah Emetulu.;Loïc Epelboin.;Gilles Eperon.;Line Medebb.;Federico Gobbi.;Martin P Grobusch.;Oula Itani.;Sabine Jordan.;Paul Kelly.;Karin Leder.;Marta Díaz-Menéndez.;Nobumasa Okumura.;Aisha Rizwan.;Camilla Rothe.;Mauro Saio.;Jesse Waggoner.;Yukihiro Yoshimura.;Michael Libman.;Davidson H Hamer.;Eli Schwartz.
来源: Ann Intern Med. 2023年176卷7期940-948页
Dengue virus is a flavivirus transmitted by Aedes mosquitoes and is an important cause of illness worldwide. Data on the severity of travel-associated dengue illness are limited.
610. Effects of Implementation of a Supervised Walking Program in Veterans Affairs Hospitals : A Stepped-Wedge, Cluster Randomized Trial.
作者: Susan N Hastings.;Karen M Stechuchak.;Ashley Choate.;Courtney Harold Van Houtven.;Kelli D Allen.;Virginia Wang.;Cathleen Colón-Emeric.;George L Jackson.;Teresa M Damush.;Cassie Meyer.;Caitlin B Kappler.;Helen Hoenig.;Nina Sperber.;Cynthia J Coffman.
来源: Ann Intern Med. 2023年176卷6期743-750页
In trials, hospital walking programs have been shown to improve functional ability after discharge, but little evidence exists about their effectiveness under routine practice conditions.
611. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
作者: Kristina L Bajema.;Kristin Berry.;Elani Streja.;Nallakkandi Rajeevan.;Yuli Li.;Pradeep Mutalik.;Lei Yan.;Francesca Cunningham.;Denise M Hynes.;Mazhgan Rowneki.;Amy Bohnert.;Edward J Boyko.;Theodore J Iwashyna.;Matthew L Maciejewski.;Thomas F Osborne.;Elizabeth M Viglianti.;Mihaela Aslan.;Grant D Huang.;George N Ioannou.
来源: Ann Intern Med. 2023年176卷6期807-816页
Information about the effectiveness of oral antivirals in preventing short- and long-term COVID-19-related outcomes in the setting of Omicron variant transmission and COVID-19 vaccination is limited.
613. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
作者: George Goshua.;Cecelia Calhoun.;Satoko Ito.;Lyndon P James.;Andrea Luviano.;Lakshmanan Krishnamurti.;Ankur Pandya.
来源: Ann Intern Med. 2023年176卷6期779-787页
Gene therapy is a potential cure for sickle cell disease (SCD). Conventional cost-effectiveness analysis (CEA) does not capture the effects of treatments on disparities in SCD, but distributional CEA (DCEA) uses equity weights to incorporate these considerations.
615. Mental Health and Health-Related Quality of Life After Firearm Injury: A Preliminary Descriptive Study.
作者: Sydney C Timmer-Murillo.;Sarah J H Melin.;Carissa W Tomas.;Timothy J Geier.;Amber Brandolino.;Andrew T Schramm.;Christine L Larson.;Terri A deRoon-Cassini.
来源: Ann Intern Med. 2023年176卷7期1010-1012页 616. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
作者: Marika M Cusick.;Rebecca L Tisdale.;Glenn M Chertow.;Douglas K Owens.;Jeremy D Goldhaber-Fiebert.
来源: Ann Intern Med. 2023年176卷6期788-797页
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have the potential to alter the natural history of chronic kidney disease (CKD), and they should be included in cost-effectiveness analyses of screening for CKD.
|